down-regulated via GnRH agonist long protocol or fixed antagonist protocol below 40 years of age. A total of 463 normoresponder cycles between January 2013 and December 2013 were retrospectively analyzed. Those with a BMI>28 kg/m [2] , any kind of uterine, ovarian or adnexial pathology, any significant systemic, endocrine or metabolic disease or who were reported as azoospermia, were excluded from the study. The patients were grouped according to the usage of micronized progesterone vaginal capsule 600 mg/day [Group 1] or progesterone vaginal gel 180 mg/day [Group 2] as luteal phase Treatment cycle characteristics and pregnancy outcomes were compared between groups. Group-I included 220 cycles and group 2 included 243 cycles. Although the MII oocyte percentage among the total number of MII oocytes was significantly higher in Group-II [77.5% and 80.2%; p=0.034] , positive beta-hCG [32.3% and 21.8%; p=0.015] and clinical pregnancy [27.3% and 17.7%; p=0.018] rates were significantly higher in Group-I. No difference was observed between groups regarding the ongoing pregnancy rates [23.2% and 17.3%; p=0.143] . Micronized progesterone vaginal capsule 600 mg daily used for luteal support in the IVF/ICSIET cycles was observed to significantly increase the biochemical and clinical pregnancy rates compared to progesterone vaginal gel 180 mg daily. However, no difference was observed between two groups regarding ongoing pregnancy rates